Long-Acting Insulin Market
Long-Acting Insulin Market Study by Detemir, Glargine, and Degludec through Delivery from Pumps, Needles & Syringes, Pens, and Injection Ports From 2024 to 2034
Analysis of Long-Acting Insulin Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Long-Acting Insulin Market Outlook (2024 to 2034)
Revenue from the global long-acting insulin market is analyzed to reach US$ 12 billion in 2024 and achieve a value of US$ 42.9 billion by the end of 2034. This latest research study by skilled analysts at Fact.MR states that worldwide demand is projected to rise at a noteworthy CAGR of 13.6% from 2024 to 2034.
Demand for long-acting insulins is increasing because of the rising number of people with diabetes, particularly Type 2. Reasons behind these are, the growing bad eating habits and sedentary lifestyles. The International Diabetes Federation projects that 643 million people worldwide are estimated to have diabetes by 2030, which is raising the demand for effective insulin treatments.
A high number of investments from pharmaceutical or healthcare companies are going into the development and production of long-acting insulins. For instance, Sanofi announced a new investment of € 1.3 billion in a new insulin plant to be constructed in Frankfurt, Germany, to increase the production potential of long-acting insulins, such as Lantus.
Availability as well as pricing of long-acting insulins directly impacts the finances of healthcare providers. Hospitals and clinics are under more financial strain because of rising insulin prices, which hurt patient access to essential medications and treatment choices. For example, research discovered that longer-acting insulin prescriptions and expenses in the following year were linked to industry marketing fees to doctors.
North America is holding market leadership due to the well-established healthcare sector and strong demand for long-acting insulins. High spending on diabetes diagnosis is further contributing to market expansion in the region. In the United States, the overall cost of treating diabetes was US$ 412.9 billion in 2022.
Direct medical costs for glucose-lowering drugs, which help diabetics control their blood sugar levels, account for a sizeable amount of these costs, estimated at around 17% in total. Long-acting insulin is included in this category, highlighting the significance of medication in the treatment of diabetes and the financial strain it places on the healthcare system. Western Europe is also a prominent region for market players due to its position as a leading manufacturer of long-acting insulin.
To attract more consumer base, several companies are launching products Continuous Glucose Monitoring (CGM). For instance, Dexcom introduced Stelo, a continuous glucose monitor that tracks blood sugar levels in real-time without a prescription. Through a smartphone app, Stelo, which costs US$ 99 each month, gives customers instant feedback and health advice to improve diabetes treatment.
According to research by Fact.MR,
- The market in North America is analyzed to achieve a valuation of US$ 4.33 billion in 2024.
- The market in South Asia & Pacific is evaluated to rise at an excellent CAGR of 16.3% from 2024 to 2034.
- Demand for glargine is projected to reach a worth of US$ 6.5 billion in 2024.
| Report Attribute | Detail |
|---|---|
| Long-Active Insulin Market Size (2024E) | US$ 12 Billion |
| Forecasted Market Value (2034F) | US$ 42.9 Billion |
| Global Market Growth Rate (2024 to 2034) | 13.6% CAGR |
| North America Market Share (2024E) | 36.1% |
| East Asia Market Value (2024E) | US$ 2.08 Billion |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 16.3% CAGR |
| Glargine Segment Value (2034F) | US$ 23.14 Billion |
| Type 2 Diabetes Segment Value (2034F) | US$ 32.76 Billion |
| Key Companies Profiled | Ganli Pharmaceutical Co. Ltd; Sanofi-Aventis U.S. LLC; Lilly USA; LLC; Novo Nordisk A/S; Biocon; Wockhardt; Mylan; Julphar |
Insulin is a hormone that is produced by the pancreas to regulate blood sugar levels. Sometimes this hormone is deficient in individuals resulting in diabetes. Long-acting insulin is given for both type 1 and type 2 diabetes. The market is mainly driven by the rise in the prevalence of diabetes, the increasing geriatric population, new product launches, and an increase in research and development.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is Driving Demand for Long-Acting Insulin?
To regulate the blood sugar levels, insulin treatment is given to the individual, which will mimic the physiological insulin secretion. The long-acting insulin is usually taken once a day and it lasts for the entire day.
The major factors driving the demand for long-acting insulin are the rise in the prevalence of diabetes, the increasing geriatric population, new product launches, and the increase in research and development. According to a report, by 2045, globally there will be 438 million people between 20-64 years who will be suffering from diabetes.
Diabetes is also caused due to overweight and obesity. According to WHO, at least 2.8 million people die due to obesity or being overweight. These people are at a higher risk of developing type 2 diabetes. This rise in the prevalence of diabetes and obesity will drive the market. According to a UN report, the geriatric population will increase from 9.3% in 2020 to around 16% in 2050.
Due to the combined effect of impaired pancreatic islet function and increasing insulin resistance with aging, this population is at a higher risk of developing type 2 diabetes.
Moreover, awareness about the current treatments by the population plays a crucial role in the surge in demand for long-acting insulin surgery during the forecast period.
Regional Outlook for Long-Acting Insulin
The market is dominated by the European region. This is due to the presence of major players in the market. Out of the three major players of long-acting insulin, two are present in Europe and are distributors of insulin in many low and middle-income countries and also in high-income countries. Apart from this, the geriatric population is high in this region. For instance, as per Eurostat reported data in 2020, more than 20% of the total population of Europe is above the age of 65.
Followed by Europe, North America is dominating the market with countries like the United States and Canada. These countries have the best healthcare infrastructure and the presence of the major players. The market is mainly driven by acquisition and collaboration.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Who are the Key Manufacturers and Suppliers of Long-Acting Insulin?
Some of the leading manufacturers operating in the long-acting insulin include
- Ganli Pharmaceutical Co. Ltd
- Sanofi-Aventis U.S. LLC
- Lilly USA
- LLC
- Novo Nordisk A/S
- Biocon
- Wockhardt
- Mylan
- Julphar
Many leading manufacturers of Long-Acting Insulin are focusing on launching new products. For instance, in August 2020, Mylan and Biocon in collaboration launched Semglee, an insulin glargine injection in the U.S.
Long-Acting Insulin Market Report Highlights:
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Segmentation of Long-Acting Insulin Market Research
-
By Product Type :
- Detemir
- Glargine
- Degludec
-
By Indication :
- Type 1 Diabetes
- Type 2 Diabetes
-
By Delivery Method :
- Pumps
- Needles & Syringes
- Pens
- Injection Ports
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Mail Order Pharmacies
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis and Forecast
- 6.1. Product Type
- 6.2. Indication
- 6.3. Delivery Method
- 6.4. Distribution Channel
- 7. Global Market Analysis and Forecast, By Product Type
- 7.1. Detemir
- 7.2. Glargine
- 7.3. Degludec
- 8. Global Market Analysis and Forecast, By Indication
- 8.1. Type 1 diabetes
- 8.2. Type 2 diabetes
- 9. Global Market Analysis and Forecast, By Delivery Method
- 9.1. Pump
- 9.2. Needle and syringe
- 9.3. Pen
- 9.4. Injection port
- 10. Global Market Analysis and Forecast, By Distribution Channel
- 10.1. Hospital Pharmacies
- 10.2. Retail Pharmacies
- 10.3. Mail Order Pharmacies
- 11. Global Market Analysis and Forecast, By Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. East Asia
- 11.6. South Asia & Pacific
- 11.7. MEA
- 12. North America Sales Analysis and Forecast, by Key Segments and Countries
- 13. Latin America Sales Analysis and Forecast, by Key Segments and Countries
- 14. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
- 16. East Asia Sales Analysis and Forecast, by Key Segments and Countries
- 17. South Asia & Pacific Sales Analysis and Forecast, by Key Segments and Countries
- 18. MEA Sales Analysis and Forecast, by Key Segments and Countries
- 19. Sales Forecast by Product Type, Indication, Delivery Method, and Distribution Channel for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Ganli Pharmaceutical Co. Ltd
- 21.2. Sanofi-Aventis U.S. LLC
- 21.3. Lilly USA
- 21.4. LLC
- 21.5. Novo Nordisk A/S
- 21.6. Biocon
- 21.7. Wockhardt
- 21.8. Mylan
- 21.9. Julphar
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Product Type
Table 3: Global Market US$ Mn Forecast by Indication
Table 4: Global Market US$ Mn Forecast by Delivery Method
Table 5: Global Market US$ Mn Forecast by Distribution Channel
Table 6: North America Market US$ Mn Forecast by Country
Table 7: North America Market US$ Mn Forecast by Product Type
Table 8: North America Market US$ Mn Forecast by Indication
Table 9: North America Market US$ Mn Forecast by Delivery Method
Table 10: North America Market US$ Mn Forecast by Distribution Channel
Table 11: Latin America Market US$ Mn Forecast by Country
Table 12: Latin America Market US$ Mn Forecast by Product Type
Table 13: Latin America Market US$ Mn Forecast by Indication
Table 14: Latin America Market US$ Mn Forecast by Delivery Method
Table 15: Latin America Market US$ Mn Forecast by Distribution Channel
Table 16: Western Europe Market US$ Mn Forecast by Country
Table 17: Western Europe Market US$ Mn Forecast by Product Type
Table 18: Western Europe Market US$ Mn Forecast by Indication
Table 19: Western Europe Market US$ Mn Forecast by Delivery Method
Table 20: Western Europe Market US$ Mn Forecast by Distribution Channel
Table 21: Eastern Europe Market US$ Mn Forecast by Country
Table 22: Eastern Europe Market US$ Mn Forecast by Product Type
Table 23: Eastern Europe Market US$ Mn Forecast by Indication
Table 24: Eastern Europe Market US$ Mn Forecast by Delivery Method
Table 25: Eastern Europe Market US$ Mn Forecast by Distribution Channel
Table 26: East Asia Market US$ Mn Forecast by Country
Table 27: East Asia Market US$ Mn Forecast by Product Type
Table 28: East Asia Market US$ Mn Forecast by Indication
Table 29: East Asia Market US$ Mn Forecast by Delivery Method
Table 30: East Asia Market US$ Mn Forecast by Distribution Channel
Table 31: South Asia & Pacific Market US$ Mn Forecast by Country
Table 32: South Asia & Pacific Market US$ Mn Forecast by Product Type
Table 33: South Asia & Pacific Market US$ Mn Forecast by Indication
Table 34: South Asia & Pacific Market US$ Mn Forecast by Delivery Method
Table 35: South Asia & Pacific Market US$ Mn Forecast by Distribution Channel
Table 36: MEA Market US$ Mn Forecast by Country
Table 37: MEA Market US$ Mn Forecast by Product Type
Table 38: MEA Market US$ Mn Forecast by Indication
Table 39: MEA Market US$ Mn Forecast by Delivery Method
Table 40: MEA Market US$ Mn Forecast by Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 4: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 5: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 7: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 8: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 9: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 10: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 13: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 14: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 15: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 17: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 18: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 19: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 20: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 22: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 23: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 24: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 25: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 26: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 27: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 28: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 29: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 30: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 31: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 32: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 33: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 34: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 35: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 36: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Product Type
Figure 37: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 38: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Delivery Method
Figure 39: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 40: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the growth outlook for the long-acting insulin market by 2034?
The long-acting insulin market is evaluated to experience substantial growth with a CAGR of 13.6% through 2034.
Which factors are driving the long-acting insulin market?
Insulin treatment, the prevalence of obesity and diabetes, increase in the geriatric population are driving the long-acting insulin market.
Which region will lead the long-acting insulin market until 2034?
North America dominates the global market due to the presence of major companies and higher geriatric population.
Long-Acting Insulin Market